FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Rogers

Research Profile

Chemicals & Drugs

Anatomy

Physiology

Living Beings

Concepts & Ideas

Structure-Activity Relationship

Co-author Network

Publications

TOP 3
Anke J Roelofs; Michael J Rogers; R Graham G Russell; Charlotte A Stewart; Shuting Sun; Frank H Ebetino; Boris A Kashemirov; Mark W Lundy; Charles E McKenna; Katarzyna M Błażewska; Fraser Coxon
Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo.
Alun Hughes; Jennifer Kleine-Albers; Stuart H Ralston; Miep H Helfrich; Michael J Rogers
A class III semaphorin (Sema3e) inhibits mouse osteoblast migration and decreases osteoclast formation in vitro.
Fraser Coxon; Michael J Rogers; Julie C Crockett
Isolation and purification of rabbit osteoclasts.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Rogers (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Anke J Roelofs; Michael J Rogers; R Graham G Russell; Charlotte A Stewart; Shuting Sun; Frank H Ebetino; Boris A Kashemirov; Mark W Lundy; Charles E McKenna; Katarzyna M Błażewska; Fraser Coxon
Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2012;27(4):835-47.
2012: Alun Hughes; Jennifer Kleine-Albers; Stuart H Ralston; Miep H Helfrich; Michael J Rogers
A class III semaphorin (Sema3e) inhibits mouse osteoblast migration and decreases osteoclast formation in vitro.
Calcified tissue international 2012;90(2):151-62.
2012: Fraser Coxon; Michael J Rogers; Julie C Crockett
Isolation and purification of rabbit osteoclasts.
Methods in molecular biology (Clifton, N.J.) 2012;816():145-58.
2011: Katarzyna M Błażewska; Fraser Coxon; Frank H Ebetino; Ralf Haiges; Boris A Kashemirov; Feng Ni; Michael J Rogers; Miguel C Seabra; Charlotte A Stewart; Rudi Baron; Charles E McKenna
Synthesis, stereochemistry and SAR of a series of minodronate analogues as RGGT inhibitors.
European journal of medicinal chemistry 2011;46(10):4820-6.
2011: Julie Crockett; Angela Duthie; John Greenhorn; Miep H Helfrich; David J Mellis; Stuart H Ralston; Kathleen Ij Shennan; Debbie I Wilkinson; Michael J Rogers
Signal peptide mutations in RANK prevent downstream activation of NF-κB.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2011;26(8):1926-38.
2011: Fraser Coxon; Frank H Ebetino; Miguel C Seabra; Charlotte A Stewart; Adam Taylor; Rudi Baron; Michael J Rogers
The gunmetal mouse reveals Rab geranylgeranyl transferase to be the major molecular target of phosphonocarboxylate analogues of bisphosphonates.
Bone 2011;49(1):111-21.
2011: Michael J Rogers; Fraser Coxon; Julie Crockett; Jukka Mönkkönen
Biochemical and molecular mechanisms of action of bisphosphonates.
Bone 2011;49(1):34-41.
2011: Keith Thompson; Kumar Vinod; Michael J Rogers; William G Simpson; Fran Keech; Robin J May; David J McLernon; David M Reid
Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.
Bone 2011;49(1):140-5.
2011: Julie C Crockett; Michael J Rogers; Fraser P Coxon; Lynne J Hocking; Miep H Helfrich
Bone remodelling at a glance.
Journal of cell science 2011;124(Pt 7):991-8.
2010: Lynne J Hocking; David J Mellis; Paul S McCabe; Miep H Helfrich; Michael J Rogers
Functional interaction between sequestosome-1/p62 and autophagy-linked FYVE-containing protein WDFY3 in human osteoclasts.
Biochemical and biophysical research communications 2010;402(3):543-8.
2010: Lesley A Ford; Anke J Roelofs; Sharon Anavi-Goffer; Luisa Mowat; Daniel G Simpson; Andrew J Irving; Michael J Rogers; Ann M Rajnicek; Ruth A Ross
A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells.
British journal of pharmacology 2010;160(3):762-71.
2010: Charles E McKenna; Boris A Kashemirov; Katarzyna M Błazewska; Isabelle Mallard-Favier; Charlotte A Stewart; Javier Rojas; Mark W Lundy; Frank H Ebetino; Rudi A Baron; James E Dunford; Marie L Kirsten; Miguel C Seabra; Joy L Bala; Mong S Marma; Michael J Rogers; Fraser Coxon
Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
Journal of medicinal chemistry 2010;53(9):3454-64.
2010: Anke J Roelofs; Fraser Coxon; Frank H Ebetino; Mark W Lundy; Zachary J Henneman; George H Nancollas; Shuting Sun; Katarzyna M Blazewska; Joy Lynn F Bala; Boris A Kashemirov; Aysha B Khalid; Charles E McKenna; Michael J Rogers
Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2010;25(3):606-16.
2010: Anke J Roelofs; Keith Thompson; Frank H Ebetino; Michael J Rogers; F P Coxon
Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.
Current pharmaceutical design 2010;16(27):2950-60.
2010: Keith Thompson; Anke J Roelofs; Marjo Jauhiainen; Hannu Mönkkönen; Jukka Mönkkönen; Michael J Rogers
Activation of γδ T cells by bisphosphonates.
Advances in experimental medicine and biology 2010;658():11-20.
2010: Andreas Guenther; Sharon Gordon; Markus Tiemann; Renate Burger; Frank Bakker; Jonathan R Green; Wolfgang Baum; Anke J Roelofs; Michael J Rogers; Martin Gramatzki
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
International journal of cancer. Journal international du cancer 2010;126(1):239-46.
2009: Lauren S Whyte; Erik Ryberg; Natalie Sims; Susan A Ridge; Ken Mackie; Peter J Greasley; Ruth A Ross; Michael J Rogers
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(38):16511-6.
2009: Johanna Räikkönen; Julie Crockett; Michael J Rogers; Hannu Mönkkönen; Seppo Auriola; Jukka Mönkkönen
Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro.
British journal of pharmacology 2009;157(3):427-35.
2009: Angela C Hirbe; Anke J Roelofs; Desiree H Floyd; Hongju Deng; Stephanie N Becker; Lisa Gooding Lanigan; Anthony J Apicelli; Zhiqiang Xu; Julie L Prior; Mark C Eagleton; David Piwnica-Worms; Michael J Rogers; Katherine Weilbaecher
The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
Bone 2009;44(5):908-16.
2009: Karen A Sutherland; Helena L Rogers; Denise Tosh; Michael J Rogers
RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.
Arthritis research & therapy 2009;11(2):R58.
2009: Anke J Roelofs; Marjo Jauhiainen; Hannu Mönkkönen; Michael J Rogers; Jukka Mönkkönen; Keith Thompson
Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.
British journal of haematology 2009;144(2):245-50.
2008: Matteo M Guerrini; Cristina Sobacchi; Barbara Cassani; Mario Abinun; Sara S Kilic; Alessandra Pangrazio; Daniele Moratto; Evelina Mazzolari; Jill Clayton-Smith; Paul Orchard; Fraser Coxon; Miep H Helfrich; Julie Crockett; David Mellis; Ashok Vellodi; Ilhan Tezcan; Luigi D Notarangelo; Michael J Rogers; Paolo Vezzoni; Anna Villa; Annalisa Frattini
Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations.
American journal of human genetics 2008;83(1):64-76.
2008: R G G Russell; N B Watts; Frank H Ebetino; Michael J Rogers
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2008;19(6):733-59.
2008: Fraser Coxon; Keith Thompson; Anke J Roelofs; Frank H Ebetino; Michael J Rogers
Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Bone 2008;42(5):848-60.
2008: James E Dunford; AARON ALFRED ASSAH KWAASI; Michael J Rogers; Bobby L Barnett; Frank H Ebetino; R Graham G Russell; Udo Oppermann; Kathryn L Kavanagh
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Journal of medicinal chemistry 2008;51(7):2187-95.
2007: Julie Crockett; Norbert Schütze; Denise Tosh; Susanne Jatzke; Angela Duthie; Franz Jakob; Michael J Rogers
The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5.
Endocrinology 2007;148(12):5761-8.
2007: R Graham G Russell; Zhidao Xia; James E Dunford; Udo Oppermann; AARON ALFRED ASSAH KWAASI; Philippa Hulley; Kathryn L Kavanagh; James T Triffitt; Mark W Lundy; Roger Phipps; Bobby L Barnett; Fraser Coxon; Michael J Rogers; Nelson B Watts; Frank H Ebetino
Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Annals of the New York Academy of Sciences 2007;1117():209-57.
2007: Alun Hughes; Michael J Rogers; Aymen I Idris; Julie Crockett
A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
Calcified tissue international 2007;81(5):403-13.
2007: Cristina Sobacchi; Annalisa Frattini; Matteo M Guerrini; Mario Abinun; Alessandra Pangrazio; Lucia Susani; R G M Bredius; Grazia Mancini; Andrew Cant; Nick Bishop; Peter Stanislaw Grabowski; Andrea Del Fattore; Chiara Messina; Gabriella Errigo; Fraser Coxon; Debbie I Scott; Anna Teti; Michael J Rogers; Paolo Vezzoni; Anna Villa; Miep H Helfrich
Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.
Nature genetics 2007;39(8):960-2.
2007: Anke J Roelofs; Claire M Edwards; R Graham G Russell; Frank H Ebetino; Michael J Rogers; Philippa Hulley
Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
The Journal of pharmacology and experimental therapeutics 2007;322(1):228-35.
2007: Liesbeth Van Wesenbeeck; Paul R Odgren; Fraser Coxon; Annalisa Frattini; Pierre Moens; Bram Perdu; Carole A MacKay; Els Van Hul; Jean-Pierre Timmermans; Filip Vanhoenacker; Ruben Jacobs; Barbara Peruzzi; Anna Teti; Miep H Helfrich; Michael J Rogers; Anna Villa; Wim Van Hul
Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans.
The Journal of clinical investigation 2007;117(4):919-30.
2007: A Taylor; Michael J Rogers; D Tosh; Fraser Coxon
A novel method for efficient generation of transfected human osteoclasts.
Calcified tissue international 2007;80(2):132-6.
2006: Anke J Roelofs; Keith Thompson; Sharon Gordon; Michael J Rogers
Molecular mechanisms of action of bisphosphonates: current status.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 2):6222s-6230s.
2006: Fraser Coxon; Keith Thompson; Michael J Rogers
Recent advances in understanding the mechanism of action of bisphosphonates.
Current opinion in pharmacology 2006;6(3):307-12.
2006: Kathryn L Kavanagh; Kunde Guo; James E Dunford; Xiaoqiu Wu; Stefan Knapp; Frank H Ebetino; Michael J Rogers; R Graham G Russell; Udo Oppermann
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(20):7829-34.
2006: James E Dunford; Michael J Rogers; Frank H Ebetino; Roger Phipps; Fraser Coxon
Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2006;21(5):684-94.
2006: Keith Thompson; Michael J Rogers; Fraser Coxon; Julie Crockett
Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis.
Molecular pharmacology 2006;69(5):1624-32.
2006: Keith Thompson; Javier Rojas-Navea; Michael J Rogers
Alkylamines cause Vgamma9Vdelta2 T-cell activation and proliferation by inhibiting the mevalonate pathway.
Blood 2006;107(2):651-4.
2005: Fraser Coxon; Frank H Ebetino; Emilie H Mules; Miguel C Seabra; Charles E McKenna; Michael J Rogers
Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Bone 2005;37(3):349-58.
2005: Steven P Luckman; David Hughes; Fraser Coxon; Graham G Russell; Michael J Rogers
JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998).
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2005;20(7):1265-74.
2004: Michael J Rogers
From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.
Calcified tissue international 2004;75(6):451-61.
2004: Keith Thompson; Michael J Rogers
Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2004;19(2):278-88.
2003: Julie Crockett; Michael J Rogers
Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2003;18(2):204-12.
2003: Michael J Rogers
New insights into the molecular mechanisms of action of bisphosphonates.
Current pharmaceutical design 2003;9(32):2643-58.
2003: Fraser Coxon; Julie Crockett; Helena L Benford; Michael J Rogers
Isolation and purification of rabbit osteoclasts.
Methods in molecular medicine 2003;80():89-99.
2003: Ada Staal; Julie Crockett; Michele H French; Joann Swartz; Timur Güngör; Thomas Harrity; Joseph Tamasi; Michael J Rogers; Jean H M Feyen
The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2003;18(1):88-96.
2003: Fraser Coxon; Michael J Rogers
The role of prenylated small GTP-binding proteins in the regulation of osteoclast function.
Calcified tissue international 2003;72(1):80-4.
2002: Sharon Gordon; Miep H Helfrich; Hamdi I A Sati; Mike Greaves; Stuart H Ralston; Dominic J Culligan; Richard L Soutar; Michael J Rogers
Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
British journal of haematology 2002;119(2):475-83.
2002: Keith Thompson; James E Dunford; Frank H Ebetino; Michael J Rogers
Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
Biochemical and biophysical research communications 2002;290(2):869-73.
2001: Fraser Coxon; Miep H Helfrich; B Larijani; Mariusz Muzylak; James E Dunford; Deborah Marshall; Alastair D McKinnon; S A Nesbitt; Michael A Horton; Miguel C Seabra; Frank H Ebetino; Michael J Rogers
Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages.
The Journal of biological chemistry 2001;276(51):48213-22.
2001: Hannu Mönkkönen; Michael J Rogers; N Makkonen; Sanna Niva; Seppo Auriola; Jukka Mönkkönen
The cellular uptake and metabolism of clodronate in RAW 264 macrophages.
Pharmaceutical research 2001;18(11):1550-5.
2001: S Suri; Jukka Mönkkönen; M Taskinen; J Pesonen; M A Blank; Roger Phipps; Michael J Rogers
Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.
Bone 2001;29(4):336-43.
2001: Julie Crockett; Jukka Mönkkönen; Seppo Auriola; Hannu Mönkkönen; Michael J Rogers
The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis.
Arthritis and rheumatism 2001;44(9):2201-10.
2001: Helena L Benford; Neil W A McGowan; Miep H Helfrich; M E Nuttall; Michael J Rogers
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.
Bone 2001;28(5):465-73.
2001: James E Dunford; Keith Thompson; Fraser Coxon; Steven P Luckman; F M Hahn; C Dale Poulter; Frank H Ebetino; Michael J Rogers
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
The Journal of pharmacology and experimental therapeutics 2001;296(2):235-42.
2000: Claire M Shipman; Karin Vanderkerken; Michael J Rogers; Jennifer M Lippitt; Kewal Asosingh; David Hughes; Ben Van Camp; R Graham G Russell; Peter I Croucher
The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
British journal of haematology 2000;111(1):283-6.
2000: Fraser Coxon; Miep H Helfrich; Robert J van't Hof; S Sebti; Stuart H Ralston; A Hamilton; Michael J Rogers
Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2000;15(8):1467-76.
2000: Michael J Rogers; Sharon Gordon; Helena L Benford; Fraser Coxon; Steven P Luckman; J Monkkonen; Julie Crockett
Cellular and molecular mechanisms of action of bisphosphonates.
Cancer 2000;88(12 Suppl):2961-78.
2000: Hannu Mönkkönen; P Moilanen; Jukka Mönkkönen; Julie Crockett; Michael J Rogers; Seppo Auriola
Analysis of an adenine nucleotide-containing metabolite of clodronate using ion pair high-performance liquid chromatography-electrospray ionisation mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications 2000;738(2):395-403.
2000: Claire M Shipman; Michael J Rogers; Karin Vanderkerken; Ben Van Camp; R Graham; G Russell; Peter I Croucher
Bisphosphonates--mechanisms of action in multiple myeloma.
Acta oncologica (Stockholm, Sweden) 2000;39(7):829-35.
1999: R Graham G Russell; Michael J Rogers; Julie Crockett; Steven P Luckman; Fraser Coxon; Helena L Benford; Peter I Croucher; Claire M Shipman; H A Fleisch
The pharmacology of bisphosphonates and new insights into their mechanisms of action.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1999;14 Suppl 2():53-65.
1999: R Graham G Russell; Michael J Rogers
Bisphosphonates: from the laboratory to the clinic and back again.
Bone 1999;25(1):97-106.
1999: Helena L Benford; Julie Crockett; Seppo Auriola; Jukka Mönkkönen; Michael J Rogers
Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.
Molecular pharmacology 1999;56(1):131-40.
1999: Michael J Rogers; Julie Crockett; Steven P Luckman; Fraser Coxon; Helena L Benford; Jukka Mönkkönen; Seppo Auriola; K M Chilton; R Graham G Russell
Molecular mechanisms of action of bisphosphonates.
Bone 1999;24(5 Suppl):73S-79S.
1999: N Makkonen; A Salminen; Michael J Rogers; Julie Crockett; Arto Urtti; Elena Azhayeva; Jukka Mönkkönen
Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 1999;8(2):109-18.
1999: John E Fisher; Michael J Rogers; J M Halasy; Steven P Luckman; David Hughes; PJ Masarachia; Gregg Wesolowski; R Graham G Russell; Gideon A Rodan; Alfred A Reszka
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(1):133-8.
1998: Claire M Shipman; Michael J Rogers; JF Apperley; R Graham; G Russell; Peter I Croucher
Anti-tumour activity of bisphosphonates in human myeloma cells.
Leukemia & lymphoma 1998;32(1-2):129-38.
1998: Claire M Shipman; Peter I Croucher; R Graham G Russell; M H Helfrich; Michael J Rogers
The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Cancer research 1998;58(23):5294-7.
1998: Steven P Luckman; Fraser Coxon; Frank H Ebetino; R Graham G Russell; Michael J Rogers
Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1998;13(11):1668-78.
1998: Fraser Coxon; Helena L Benford; R Graham G Russell; Michael J Rogers
Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs.
Molecular pharmacology 1998;54(4):631-8.
1998: Steven P Luckman; David Hughes; Fraser Coxon; R Graham; G Russell; Michael J Rogers
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1998;13(4):581-9.
1997: Seppo Auriola; Julie Crockett; Michael J Rogers; A Koivuniemi; Jukka Mönkkönen
Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications 1997;704(1-2):187-95.
1997: Michael J Rogers; DJ Watts; RG Russell
Overview of bisphosphonates.
Cancer 1997;80(8 Suppl):1652-60.
1997: Claire M Shipman; Michael J Rogers; JF Apperley; R Graham G Russell; Peter I Croucher
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
British journal of haematology 1997;98(3):665-72.
1997: Julie Crockett; Jukka Mönkkönen; G Michael Blackburn; R Graham G Russell; Michael J Rogers
Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1997;12(9):1358-67.
1997: Michael J Rogers; X Xiong; X Ji; Jukka Mönkkönen; RG Russell; M P Williamson; Frank H Ebetino; DJ Watts
Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake.
Pharmaceutical research 1997;14(5):625-30.
1996: Michael J Rogers; K M Chilton; Fraser Coxon; John Lawry; MO Smith; S Suri; R Graham G Russell
Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1996;11(10):1482-91.
1996: Michael J Rogers; R J Brown; V Hodkin; G Michael Blackburn; R Graham G Russell; DJ Watts
Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes.
Biochemical and biophysical research communications 1996;224(3):863-9.
1995: Michael J Rogers; X Xiong; R J Brown; DJ Watts; R Graham G Russell; A V Bayless; Frank H Ebetino
Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae.
Molecular pharmacology 1995;47(2):398-402.
1994: Michael J Rogers; X Ji; R Graham G Russell; G Michael Blackburn; Michael P Williamson; A V Bayless; Frank H Ebetino; DJ Watts
Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum.
The Biochemical journal 1994;303 ( Pt 1)():303-11.
1994: Michael J Rogers; DJ Watts; R Graham G Russell; X Ji; X Xiong; G Michael Blackburn; A V Bayless; Frank H Ebetino
Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1994;9(7):1029-39.
1992: Michael J Rogers; R Graham G Russell; G Michael Blackburn; Michael P Williamson; DJ Watts
Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum.
Biochemical and biophysical research communications 1992;189(1):414-23.